BLS Pharmaceuticals (ASX:BLS) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:BLS BLS Pharmaceuticals Ltd ASX:BLS
46 GF Score
Price A$0.97
GF Value A$0.69
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is BLS Pharmaceuticals Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ASX:BLS
46GF Score
BLS Pharmaceuticals Ltd ASX:BLS
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BLS Pharmaceuticals (ASX:BLS) Overvalued in 2026?

Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued. The current stock price of A$0.97 is trading 40.6% above its estimated GF Value™ of A$0.69. GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ASX:BLS:

  • Short Ratio:
  • GF Value™: A$0.69 vs. price of A$0.97 (40.6% above fair value)
  • GF Score™: 46/100 with 8 warning signs

No single metric tells the full story. See the ASX:BLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BLS Pharmaceuticals Business Description

Other Exchanges PR80:Germany
Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
46GF Score

Get the complete analysis for ASX:BLS

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.97
Price
A$0.69
GF Value